Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

• Published in: Cancers Vol. 12; no. 4; p. 869
• Main Authors: Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S, Gunter, Jennifer H, Sullivan, Mitchell A, Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M, Broomfield, Amy, Gough, Madeline, Wu, Andy C, McGann, Thomas, Weroha, S John, Haluska, Paul, Forbes, Josephine M, Armes, Jane E, Barry, Sinead C, Coward, Jermaine I, Jagasia, Nisha, Chetty, Naven, Snell, Cameron E, Lourie, Rohan, Perrin, Lewis C, Hooper, John D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.04.2020; MDPI
• Subjects: Acidification; Animal models; Cancer therapies; Carboplatin; Cell culture; Chemotherapy; Clinical trials; Glucose; Glycogen; Medical prognosis; Metabolism; Ovarian cancer; Ovarian carcinoma; Patients; Xenografts; 2DG; clear cell ovarian cancer; glycogen
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12040869

High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses-of more than 10-fold lower than previously reported for other cancers-significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.